Abstract
Cognitive dysfunction is a hallmark feature of schizophrenia and is evident across all phases of the illness. While prior metaanalyses have elucidated the level and pattern of cognitive deficits in the premorbid and post-onset periods of psychosis, no metaanalyses of studies of the putative prodromal period have been published. Our primary aim is to provide a meta-analysis of neurocognitive findings from 14 studies of psychosis risk syndrome (PRS) individuals published through February 2011, and compare the resulting profile with that synthesized by meta-analyses from other periods of the disorder. Meta-analysis of 1215 PRS individuals with a mean age of 19.2 (± 3.3) and 851 healthy control subjects yielded small-to-medium impairments across nine of 10 neurocognitive domains (Cohens d = -0.26 to -0.67). Seven studies reported on PRS individuals who later developed psychosis (n = 175) and their baseline performance level generally yielded moderate-to-large ESs (d = -0.35 to -0.84). Mild cognitive deficits are reliably and broadly present in PRS individuals, falling at a level that is intermediate between healthy individuals and those diagnosed with schizophrenia, and at a level that is comparable to those at familial (“genetic”) risk and with premorbid data. Moreover, baseline neurocognition in PRS individuals who converted to psychosis showed more severe deficits than non-converters in nearly all domains. However, considerable heterogeneity of ESs across studies in many domains underscores variability in phenotypic expression and/or measurement sensitivity, and a critical need for improved reporting of sample characteristics to support moderator variable analyses.
Keywords: Schizophrenia, psychosis, prodrome, clinical high risk, neurocognition, meta-analysis, psychosis risk syndrome (PRS), gray matter volume, cohort assessments, DSM-IV diagnoses
Current Pharmaceutical Design
Title: Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review
Volume: 18 Issue: 4
Author(s): Anthony J. Giuliano, Huijun Li, Raquelle I. Mesholam-Gately, Shannon M. Sorenson, Kristen A. Woodberry and Larry J. Seidman
Affiliation:
Keywords: Schizophrenia, psychosis, prodrome, clinical high risk, neurocognition, meta-analysis, psychosis risk syndrome (PRS), gray matter volume, cohort assessments, DSM-IV diagnoses
Abstract: Cognitive dysfunction is a hallmark feature of schizophrenia and is evident across all phases of the illness. While prior metaanalyses have elucidated the level and pattern of cognitive deficits in the premorbid and post-onset periods of psychosis, no metaanalyses of studies of the putative prodromal period have been published. Our primary aim is to provide a meta-analysis of neurocognitive findings from 14 studies of psychosis risk syndrome (PRS) individuals published through February 2011, and compare the resulting profile with that synthesized by meta-analyses from other periods of the disorder. Meta-analysis of 1215 PRS individuals with a mean age of 19.2 (± 3.3) and 851 healthy control subjects yielded small-to-medium impairments across nine of 10 neurocognitive domains (Cohens d = -0.26 to -0.67). Seven studies reported on PRS individuals who later developed psychosis (n = 175) and their baseline performance level generally yielded moderate-to-large ESs (d = -0.35 to -0.84). Mild cognitive deficits are reliably and broadly present in PRS individuals, falling at a level that is intermediate between healthy individuals and those diagnosed with schizophrenia, and at a level that is comparable to those at familial (“genetic”) risk and with premorbid data. Moreover, baseline neurocognition in PRS individuals who converted to psychosis showed more severe deficits than non-converters in nearly all domains. However, considerable heterogeneity of ESs across studies in many domains underscores variability in phenotypic expression and/or measurement sensitivity, and a critical need for improved reporting of sample characteristics to support moderator variable analyses.
Export Options
About this article
Cite this article as:
J. Giuliano Anthony, Li Huijun, I. Mesholam-Gately Raquelle, M. Sorenson Shannon, A. Woodberry Kristen and J. Seidman Larry, Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316019
DOI https://dx.doi.org/10.2174/138161212799316019 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Demonstration of Advanced Data Mining Tools for Optimization of Pellets Employing Modified Extrusion-pelletization Technique
Current Drug Therapy Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology The Alzheimer Pandemic: Is Paracetamol to Blame?
Inflammation & Allergy - Drug Targets (Discontinued) Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Phytochemicals for Human Diseases: An Update)
Current Pharmaceutical Biotechnology Therapeutic Properties of Several Chemical Compounds of <i>Salvia officinalis</i> L. in Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Sulfur-containing Secondary Metabolites as Neuroprotective Agents
Current Medicinal Chemistry Acid Sensing Ion Channels and Acid Nociception
Current Pharmaceutical Design Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Chinese Herbs and Herbal Extracts for Neuroprotection of Dopaminergic Neurons and Potential Therapeutic Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Psychobiological Model of Personality: Guidelines for Pharmacotherapy of Personality Disorder
Current Psychopharmacology Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Role of Complement Systems in IVIG Mediated Attenuation of Cognitive Deterioration in Alzheimer's Disease
Current Alzheimer Research Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?
Current Medicinal Chemistry Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research